🇺🇸 FDA

Intelligence · Patent portfolio

Agios Netherlands Patents

Full USPTO pharma patent portfolio for Agios Netherlands — grant dates, expiration, and drug cross-links.

Patents
93
Expiring ≤24m
0

Quick answer

Agios Netherlands has 93 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 2

  1. US 10093654

    Therapeutically active compounds and their methods of use

    Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10087172

    Compounds and their methods of use

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10087169

    Bicyclic PKM2 activators

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10029987

    Therapeutic compounds and compositions

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10028961

    Therapeutically active compounds and their methods of use

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10017495

    Therapeutically active compounds and their methods of use

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10011574

    Glutaminase inhibitors and method of use

    Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10000479

    Compounds and their methods of use

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9982309

    Method for treating cell proliferation related disorders

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9980961

    Pyruvate kinase activators for use in therapy

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9968595

    Pharmaceutical compositions of therapeutically active compounds

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9938259

    Therapeutic compositions and related methods of use

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9889137

    Therapeutically active compounds and their methods of use

    Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9856279

    Therapeutically active compositions and their methods of use

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9850277

    Therapeutically active compositions and their methods of use

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9738625

    Therapeutically active compounds and their methods of use

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9732062

    Therapeutically active compounds and their methods of use

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9724350

    N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9694013

    Therapeutically active compounds and their methods of use

    Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9682080

    Pyruvate kinase activators for use in therapy

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9662327

    Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9657004

    Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9656999

    Therapeutically active compounds and their methods of use

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9618514

    Methods of evaluating patients using E-cadherin and vimentin

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9579324

    Therapeutically active compounds and their methods of use

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9512107

    Therapeutically active compositions and their methods of use

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9474779

    Therapeutically active compositions and their methods of use

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9458132

    Therapeutic compounds and compositions and their use as PKM2 modulators

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9403792

    Methods of using pyruvate kinase activators

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9404081

    Pyruvate kinase activators for use in therapy

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9388164

    Methods of using pyruvate kinase activators

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9365545

    Therapeutic compounds and compositions

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9328077

    Bicyclic PKM2 activators

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9303002

    Compounds and their methods of use

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9221792

    N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9199968

    Therapeutic compounds and compositions

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9193701

    Pyruvate kinase activators for use in therapy

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9181231

    Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9115086

    Therapeutic compositions and related methods of use

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9108921

    Therapeutic compounds and compositions

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8889667

    Therapeutic compounds and compositions

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8883438

    Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8785450

    Therapeutic compounds and compositions

    Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8742119

    Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8501953

    PKM2 modulators for use in the treatment of cancer

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Agios Netherlands have?

93 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Agios Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.